sacituzumab govitecan
sacituzumab govitecan: sourced relationships with 1 company · 29 clinical trials tracked.
sacituzumab govitecan evidence translation
What we can confirm
29 tracked trials
What it means
What to watch
Prepared research question
How could sacituzumab govitecan → IMMU affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 2 study sponsors
Related indications
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| IMMUNOMEDICS INC (IMMU) metastatic triple-negative breast cancer (mTNBC) | Phase 3 |
Clinical Trial Registry Records (29)showing 10 most recent
NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
Primary endpoint: Cohort I: 3-year event-free survival (EFS)
Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Primary endpoint: Disease Control
A Single-Arm, Phase II Prospective Study Of Lucanoximab Combined With Tagolimab As Neoadjuvant Therapy For Resectable Head And Neck Squamous Cell Carcinoma
Primary endpoint: Major Pathological Response Rate (MPR)
Phase Ib Randomized Open-label Trial of Sacituzumab Govitecan Plus Nivolumab or Sacituzumab Govitecan Plus Nivolumab and Relatlimab as Second-line Therapy for Patients With Metastatic Triple Negative Breast Cancer
Primary endpoint: Incidence and severity of dose limiting toxicities in patients treated with sacituzumab govitecan combinations
Phase I/II Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Primary endpoint: Safety and Adverse Events (AEs)
A Phase II Study of Sacituzumab Govitecan in Combination With Cetuximab in Patients With Recurrent Metastatic HNSCC That Has Progressed After First-Line Therapy
Primary endpoint: Objective Response Rate
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Primary endpoint: Overall Survival (OS)
NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan Versus Sacituzumab Govitecan+Pembrolizumab in Low-risk, Triple-negative Early Breast Cancer (ADAPT-TN-III)
Primary endpoint: pathological complete remission (pCR)
A Multicenter, Open Label, Two Cohort, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of the Anti-TROP2 Antibody-drug Conjugate Sacituzumab Govitecan in Patients With Advanced Differentiated and Anaplastic Thyroid Neoplasms.
Primary endpoint: Objective response rate (ORR)
A Phase II Study of Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma Patients
Primary endpoint: Overall objective response rates (ORR)
Frequently asked questions
Which companies have sourced relationships with sacituzumab govitecan?
sacituzumab govitecan has dated SEC/FDA relationship records for IMMUNOMEDICS INC.
How many clinical trials involve sacituzumab govitecan?
BioSniper tracks 29 clinical trials involving sacituzumab govitecan.